Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease

Completed · Phase 2

Conditions studied: Parkinson Disease

In brief

The investigators are interested in evaluating the use of oral N-acetylcysteine (NAC) as therapy for Parkinson's Disease (PD) and measuring changes in brain and blood chemistry.

Key facts

Study ID

NCT02212678

Run by

University of Minnesota

People needed

8

Starts

2014-09-01

Expected to finish

2015-09-01

Last updated by the study team

2019-05-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All participants must be 18 years or older
• All enrollees must understand and cooperate with requirements of the study in the opinion of the investigators and must be able to provide written informed consent
• Individuals with medically stable Parkinson's disease (in the opinion of the investigator)
• All participants must not have taken antioxidants NAC, glutathione, coenzyme Q-10, vitamin C, or vitamin E for 3 weeks prior to the study
• Absence of dementia in all subjects

You may not qualify if…

• Inability to undergo MRI scanning without sedation and other MRI counterindications, such as metal in the body (see section 7.3)
• Medically unstable conditions as determined by the investigators
• Pregnant or lactating or those women of child-bearing age that are not using acceptable forms of contraception
• Diagnosis of asthma that is presently being treated with any medication, or past history of asthma/bronchospasm resulting in an emergency room visit, hospitalization or treatment
• Unable to adhere to study protocol for whatever reason

Where it is running

• University of Minnesota — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.